SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
1-Year Return
40.04%
This Quarter Return
+8.55%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$102M
AUM Growth
-$1.25M
(-1.2%)
Cap. Flow
-$3.93M
Cap. Flow
% of AUM
-3.88%
Top 10 Holdings %
Top 10 Hldgs %
59.23%
Holding
86
New
20
Increased
24
Reduced
14
Closed
28
Top Buys
| 1 |
Verastem
VSTM
|
$3.1M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$2.84M |
| 3 |
Ardelyx
ARDX
|
$2.18M |
| 4 |
ITOS
iTeos Therapeutics
ITOS
|
$1.99M |
| 5 |
Nektar Therapeutics
NKTR
|
$1.3M |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
$7.23M |
| 2 |
UroGen Pharma
URGN
|
$3.69M |
| 3 |
Aquestive Therapeutics
AQST
|
$3.04M |
| 4 |
Establishment Labs
ESTA
|
$2.88M |
| 5 |
Galapagos
GLPG
|
$2.36M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Myomo
MYO
$38.2M
| $988K | 0.97% |
457,419
+180,712
| +65% | +$390K |
|
27
Rezolute
RZLT
$642M
| $977K | 0.96% |
+219,000
| New | +$977K |
|
28
Xeris Biopharma Holdings
XERS
$1.27B
| $958K | 0.94% |
205,100
+102,835
| +101% | +$480K |
|
29
PMV Pharmaceuticals
PMVP
$76.3M
| $897K | 0.88% |
845,968
+215,785
| +34% | +$229K |
|
30
Syndax Pharmaceuticals
SNDX
$1.39B
| $870K | 0.85% |
+92,900
| New | +$870K |
|
|
GRCE
31
Grace Therapeutics, Inc. Common Stock
GRCE
$42.3M
| $869K | 0.85% |
292,500
-2,050
| -0.7% | -$6.09K |
|
32
Kezar Life Sciences
KZR
$28M
| $778K | 0.76% |
169,859
+69,859
| +70% | +$320K |
|
33
AngioDynamics
ANGO
$436M
| $765K | 0.75% |
+77,141
| New | +$765K |
|
34
Achieve Life Sciences
ACHV
$143M
| $753K | 0.74% |
+333,333
| New | +$753K |
|
35
Aclaris Therapeutics
ACRS
$224M
| $698K | 0.68% |
491,300
-36,542
| -7% | -$51.9K |
|
36
Vir Biotechnology
VIR
$714M
| $655K | 0.64% |
130,000
-14,628
| -10% | -$73.7K |
|
|
BIOA
37
BioAge Labs, Inc. Common Stock
BIOA
$169M
| $624K | 0.61% |
151,085
+101,085
| +202% | +$417K |
|
38
Liquidia Corp
LQDA
$2.48B
| $623K | 0.61% |
+50,000
| New | +$623K |
|
39
AN2 Therapeutics
ANTX
$34.4M
| $577K | 0.57% |
+544,494
| New | +$577K |
|
40
Kiora Pharmaceuticals
KPRX
$9.37M
| $513K | 0.5% |
178,000
-22,647
| -11% | -$65.2K |
|
41
Spero Therapeutics
SPRO
$120M
| $455K | 0.45% |
+156,888
| New | +$455K |
|
42
HilleVax
HLVX
$105M
| $450K | 0.44% |
226,009
-12,941
| -5% | -$25.8K |
|
|
THTX
43
Theratechnologies
THTX
$149M
| $446K | 0.44% |
189,051
+163,226
| +632% | +$385K |
|
44
Pulmonx
LUNG
$70.9M
| $378K | 0.37% |
+145,900
| New | +$378K |
|
45
Health Catalyst
HCAT
$232M
| $377K | 0.37% |
+100,000
| New | +$377K |
|
|
46
Establishment Labs
ESTA
$1.12B
| $299K | 0.29% |
7,000
-67,500
| -91% | -$2.88M |
|
47
Dynavax Technologies
DVAX
$1.17B
| $298K | 0.29% |
+30,000
| New | +$298K |
|
48
Abeona Therapeutics
ABEO
$352M
| $256K | 0.25% |
+45,000
| New | +$256K |
|
49
Savara
SVRA
$619M
| $194K | 0.19% |
85,000
+55,921
| +192% | +$128K |
|
50
IN8bio
INAB
$9.9M
| $172K | 0.17% |
+82,430
| New | +$172K |
|